Safety & Efficacy of Gratisovir (Sofosbuvir)- Ribavirin Therapy in

Status Enrolling by invitation

Clinical Trial Summary

Evaluation of Safety and Efficacy of Gratisovir (Sofosbuvir)- Ribavirin Therapy in Egyptian Pediatric Patients With Chronic Hepatitis C Infection aged 10- 18 years old.

Clinical Trial Description

Male or female child ≥ 10 years and ≤ 18 years of age chronically infected with hepatitis C virus, willing and able to complete all study visits and procedures. Acceptance from the parents will be recruited for giving a verbal and written informed consent. Patient with childs Pugh class B or C, compensated cirrhosis may be enrolled. Patient with cirrhosis with their alpha fetoprotein is more than 100 ng/ml and patient with coinfection of Hepatitis B virus or HIV will be excluded. Participation in the study procedures is anticipated to last up to 40 weeks including a screening and eligibility assessment phase (4 weeks duration), a 24- week treatment phase, and 12- week post treatment follow up phase.

A detailed treatment log of the returned investigational product will be established with the investigator (or the pharmacist) and countersigned by the investigator and the monitoring team.

Compliance is assessed by counting the number of returned tablets at each visit.

A discontinuation is defined as a period with at least seven consecutive days without study drug intake.

Safety and efficacy will be compared between cirrhotic versus non-cirrhotic subjects in multivariate model to test the impact of this pretreatment characteristic on safety, tolerability and efficacy endpoints.

Safety analysis:clinical adverse events will be displayed by body system (soc) for each study subject and by treatment group, using MedDRA coding. Summary of statistics of safety and efficacy endpoints will be displayed by stratification parameters. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Pharmacological Action

Clinical Trial Details

NCT number	NCT02985281
Study type	Interventional
Source	National Liver Institute, Egypt
Contact
Status	Enrolling by invitation
Phase	Phase 2/Phase 3
Start date	December 2016
Completion date	September 2017

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06040853` - Postoperative Pain in Laparoscopic Radical Prostatectomy Surgery With Tranexamic Acid: Analgesia? Hiperalgesia?	Phase 4
Not yet recruiting	`NCT05553496` - Assessment of Rituximab Therapeutic Response Versus Conventional Treatment	Phase 2/Phase 3
Recruiting	`NCT05534802` - Ulinastatin Improves and Prevents Cardiac Dysfunction Induced by Cardiopulmonary Bypass	N/A
Recruiting	`NCT04190537` - PARADOX - the Incidence of Paradoxical Reactions in Pediatric Patients Premedicated With Midazolam
Completed	`NCT03119454` - "Corticoid-16" in Long Term When Administered Systemically in Patients in Routine Medical Practice	N/A
Completed	`NCT03522532` - Dental Restorations Effect on Oxidative Status of the Gingival Crevicular Fluid	N/A
Unknown status	`NCT01614353` - Medication-taking Preferences & Practices of Patients With Chronic Conditions	N/A
Completed	`NCT03714360` - The Effect of Tranexamic Acid. A Randomised Study of Patients Undergoing Elective Lumbar Spine Surgery.	Phase 4
Recruiting	`NCT03352622` - Pharmacogenomic in Colombian Patients With Rheumatoid Arthritis	N/A
Recruiting	`NCT06288841` - Efficacy and Safety of Liposomal Bupivacaine Under ERAS Concept for Postoperative Analgesia of Ultrasound-Guided QLB in Gynecologic Laparoscopic Patients: A Randomized, Single-blind, Active-Controlled Clinical Study	N/A
Not yet recruiting	`NCT04320277` - Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.	Phase 2/Phase 3
Completed	`NCT03359590` - Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients	Phase 2
Completed	`NCT05591105` - Morphine Consumption in the Obese Patients
Not yet recruiting	`NCT03904303` - Test of a New Gel-based Colon Cleansing Agent Compared to Moviprep	Phase 1
Not yet recruiting	`NCT05453045` - Pharmacokinetics and Excretion of Albendazole and Its Metabolites in Saliva	N/A
Completed	`NCT05428683` - Intravitreal Triamcinolone and Moxifloxacin Injection After Cataract Surgery	N/A
Recruiting	`NCT06222710` - Ultrasound Guiding Pharmacopuncture Therapy for Supraspinatus Tendinopathy	N/A
Not yet recruiting	`NCT03953287` - Pharmacokinetic Study of Paracetamol.	Phase 1
Recruiting	`NCT03622047` - Comparison of Epidural Labor Analgesia With Dexmedetomidine or Sufentanil	N/A
Active, not recruiting	`NCT06324370` - Exploratory Pharmacokinetic Study of Virgin Coconut Oil (VCO)	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Safety and Efficacy of Gratisovir (Sofosbuvir)- Ribavirin Therapy in Pediatric Patients

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms